Atomo Diagnostics Limited

Equities

AT1

AU0000080327

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 02:10:44 2024-04-26 am EDT 5-day change 1st Jan Change
0.03 AUD 0.00% Intraday chart for Atomo Diagnostics Limited -3.23% +36.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order MT
Atomo Diagnostics Wins Order to Supply AU$970,000 Worth of HIV Self-Tests MT
Transcript : Atomo Diagnostics Limited, H1 2024 Earnings Call, Feb 26, 2024
Atomo Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Transcript : Atomo Diagnostics Limited, Q2 2024 Earnings Call, Jan 30, 2024
Atomo Diagnostics Limited Announces the Resignation of Curt LaBelle as Non-Executive Director CI
Actinogen Medical Names CFO MT
Atomo Diagnostics CFO to Step Down MT
Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023 CI
Transcript : Atomo Diagnostics Limited - Shareholder/Analyst Call
Transcript : Atomo Diagnostics Limited, Q1 2024 Earnings Call, Oct 26, 2023
Atomo Diagnostics Expands Footprint of HIV Self-Test Kit MT
Seattle-based startup makes 'beanless coffee' to help combat deforestation RE
Transcript : Atomo Diagnostics Limited, 2023 Earnings Call, Aug 24, 2023
Atomo Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Atomo Diagnostics Raises AU$2.3 Million Via Placement, Share Purchase Plan MT
Transcript : Atomo Diagnostics Limited, Q4 2023 Earnings Call, Jul 27, 2023
Atomo Diagnostics Raising AU$4 Million Via Placement, Share Purchase Plan MT
Atomo Diagnostics Signs Deal to Supply HIV Tests to Europe MT
Transcript : Atomo Diagnostics Limited - Special Call
Atomo Diagnostics Secures Nearly $2 Million Supply Deal for HIV Self-Test in South Africa MT
Atomo Diagnostics Secures AU$900,000 HIV Self-Tests Order MT
Atomo Diagnostics Limited Announces Significant Purchase Order for HIV Self-Tests for Europe CI
Atomo Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Atomo Diagnostics Limited Announces Change of Company Secretary, Effective March 1, 2023 CI
Chart Atomo Diagnostics Limited
More charts
Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. AT1 Stock
  4. News Atomo Diagnostics Limited
  5. Atomo Diagnostics Posts Higher Fiscal Q4 Revenue, Cash Receipts